SCHEMBL16003239

SCHEMBL16003239

Cc1cc(N(C)CCN(C)C)ccc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100B P04271 1/20 0.55
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
TSHR P16473 1/20 0.42
NOS1 P29475 2/20 0.42
APAF1 O14727 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
SKP2 Q13309 1/20 0.37
ESR1 P03372 2/20 0.34
AR P10275 1/20 0.34
ESR2 Q92731 1/20 0.34
BRD4 O60885 1/20 0.34
HDAC2 Q92769 1/20 0.34
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
HTR7 P34969 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10955324 0.94 S100B (0.60) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL29740664 0.94 S100B (0.60) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL13626628 0.85 TDP1 (0.42) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL5550263 0.84 S100B (0.53) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL15453003 0.81 S100B (0.69) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL10420297 0.81 S100B (0.50) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL5502903 0.81 S100B (0.50) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL16003510 0.80 CYP3A4 (0.41) ALDH1A1CYP3A4TSHRNOS1HRH3
SCHEMBL9484916 0.80 S100B (0.53) S100BALDH1A1CYP3A4TDP1TSHR
SCHEMBL5500237 0.80 S100B (0.49) S100BALDH1A1CYP3A4TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014134308-A1 SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS AMGEN INC. (US) 2014-09-04 WO disclosed